You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

~ Buy the DIMETHYL SULFOXIDE Drug Excipient Business Development Opportunity Report, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR DIMETHYL SULFOXIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for DIMETHYL SULFOXIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00118313 ↗ Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma Completed National Cancer Institute (NCI) Phase 1 2004-11-04 RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Giving vaccine therapy together with imiquimod after surgery may help the body kill any remaining tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best way to give vaccine therapy with or without imiquimod in treating patients who have undergone surgery for stage II, stage III, or stage IV melanoma.
NCT00118313 ↗ Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma Completed Craig L Slingluff, Jr Phase 1 2004-11-04 RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Giving vaccine therapy together with imiquimod after surgery may help the body kill any remaining tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best way to give vaccine therapy with or without imiquimod in treating patients who have undergone surgery for stage II, stage III, or stage IV melanoma.
NCT00317070 ↗ Trial Comparing Intravesical Cocktail With Intravesical Dimethyl Sulfoxide (DMSO) in Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC) Terminated Nova Scotia Health Authority Phase 2 2006-04-01 The primary objective of this study is to evaluate the efficacy and tolerability of the intravesical cocktail and its comparison with intravesical DMSO in a controlled trial for the treatment of painful bladder syndrome including interstitial cystitis.
NCT00388687 ↗ Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer Unknown status Medical University of Vienna 2006-07-01 The aim of this study is to visualize the tumor hypoxic tissue, the potential quantitative changes and the biological behavior of cervical carcinoma (primary and / or lymph nodes) before, during and after radiochemotherapy with the novel hypoxia PET tracer 18FAZA.
NCT00583219 ↗ Botulin-A Toxin Instillations and Overactive Bladder Completed Mayo Clinic Phase 1/Phase 2 2006-03-01 The primary objective of this pilot study is to evaluate the safety and efficacy of direct instillations of Botulinum-A toxin/DMSO into the bladder via a catheter system as a means of treating women with symptoms of overactive bladder and secondary urinary incontinence. In doing so, we will focus on estimating the percentage of women who experience an improvement in their urinary incontinence symptoms at one month and three months following this novel instillation technique.
NCT00667095 ↗ Over Active Bladder Instillation Study - Botox Terminated Mayo Clinic Phase 3 2008-04-01 The purpose of this study is to determine whether women with overactive bladder (OAB) who receive direct instillation via a catheter of a Botulinum-A Toxin (Botox) with Dimethyl Sulfoxide (DMSO) solution experience significantly better improvement of their OAB symptoms when compared to a similar group of women with OAB who receive instillation of DMSO only.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DIMETHYL SULFOXIDE

Condition Name

Condition Name for DIMETHYL SULFOXIDE
Intervention Trials
Hematopoietic and Lymphoid Cell Neoplasm 5
Refractory Lymphoma 4
Refractory Malignant Solid Neoplasm 4
Refractory Plasma Cell Myeloma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DIMETHYL SULFOXIDE
Intervention Trials
Neoplasms 7
Cystitis, Interstitial 5
Melanoma 5
Lymphoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DIMETHYL SULFOXIDE

Trials by Country

Trials by Country for DIMETHYL SULFOXIDE
Location Trials
United States 111
Israel 3
Egypt 2
Italy 2
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for DIMETHYL SULFOXIDE
Location Trials
Pennsylvania 8
Florida 5
Texas 3
Washington 3
Oregon 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DIMETHYL SULFOXIDE

Clinical Trial Phase

Clinical Trial Phase for DIMETHYL SULFOXIDE
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2/Phase 3 3
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DIMETHYL SULFOXIDE
Clinical Trial Phase Trials
Completed 12
Active, not recruiting 7
Unknown status 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DIMETHYL SULFOXIDE

Sponsor Name

Sponsor Name for DIMETHYL SULFOXIDE
Sponsor Trials
National Cancer Institute (NCI) 12
GlaxoSmithKline 2
Mayo Clinic 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DIMETHYL SULFOXIDE
Sponsor Trials
Other 29
NIH 12
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.